Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US-2022257663-A1 · Aug 18, 2022 · US
US12558380B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12558380-B2 |
| Application number | US-202217719473-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 13, 2022 |
| Priority date | Mar 15, 2013 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells.
Opening claim text (preview).
The invention claimed is: 1 . A method of differentiating pluripotent stem cells, comprising: (a) culturing a preparation of adherent pluripotent stem cells in the presence of a BMP inhibitor to produce PAX6(+), OCT4(−) cells; (b) culturing the PAX6(+), OCT4(−) cells in the absence of a BMP inhibitor to produce PAX6(+), CHX10(+) retinal neural progenitor cells; and (c) culturing the PAX6(+), CHX10(+) retinal neural progenitor cells as cell aggregates in a suspension culture. 2 . The method of claim 1 , wherein the pluripotent stem cells are embryonic stem cells or induced pluripotent stem cells. 3 . The method of claim 1 , wherein the preparation of adherent pluripotent stem cells is cultured in feeder-free conditions. 4 . The method of claim 1 , wherein the preparation of adherent pluripotent stem cells is cultured in a medium comprising the BMP inhibitor and further comprising at least one of a Wnt inhibitor, a TGFβ inhibitor, or IGF-1. 5 . The method of claim 4 , wherein the preparation of adherent pluripotent stem cells is cultured in a medium comprising a TGFβ inhibitor, optionally wherein the TGFβ inhibitor is SB431542. 6 . The method of claim 4 , wherein the preparation of adherent pluripotent stem cells is cultured in a medium comprising a Wnt inhibitor, optionally wherein the Wnt inhibitor is DKK1. 7 . The method of claim 4 , wherein the preparation of adherent pluripotent stem cells is cultured in a medium comprising a BMP inhibitor, a Wnt inhibitor, and a TGFβ inhibitor. 8 . The method of claim 4 , wherein the preparation of adherent pluripotent stem cells is cultured in a medium comprising a BMP inhibitor, a Wnt inhibitor, a TGFβ inhibitor, and IGF-1. 9 . The method of claim 1 , wherein step (a) comprises culturing the adherent pluripotent stem cells in a medium comprising a BMP inhibitor, a Wnt inhibitor, and IGF-1 for 1-10 days.
Artificially induced pluripotent stem cells, e.g. iPS · CPC title
Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696) · CPC title
from embryonic cells · CPC title
Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain · CPC title
of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.